All news

Guggenheim raises target for Elevance Health stock to USD 460

Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash

Guggenheim has increased its price target for Elevance Health (ELV) stock to USD 460, maintaining a "Buy" rating. This adjustment reflects improved performance across the company's Medicaid, Medicare Advantage, and ACA businesses, as well as higher 2027 earnings estimates. Investors are awaiting Elevance Health's third-quarter 2026 results on October 21, 2026, which will further clarify the company's financial trajectory.

Read original source

ELV company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.